Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 14;71(6):1379–1389. doi: 10.1093/cid/ciz999

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — Weight trends in participants initiating antiretroviral therapy. A, Baseline median CD4 cell count and median weight in the indicated clinical trials, which are ordered by date of trial initiation. Error bars represent the first through third quartiles. B, Mean weight change observed at the 48-week time point for the indicated trials, which are organized by date of initiation. Red bars are the investigational regimen, and gray bars are the comparator. *P < .05 by analysis of variance. C, Median weight (red) and median weight change (blue) over time in 8 pooled clinical trials. D, Body mass index category distributions over time in 8 pooled clinical trials. Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV/r, ritonavir-boosted atazanavir; B, bictegravir; C, cobicistat; D4T, stavudine; DTG, dolutegravir; E, elvitegravir; EFV, efavirenz; F, emtricitabine; RPV, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.